NCT06733519尚未招募2 期
Evaluation of TH104 for Moderate to Severe Pruritus in Primary Biliary Cholangitis: a Double-blind, Randomized, Placebo-controlled, Phase 2a Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 40
- 主要终点
- The primary objective is to investigate the safety and tolerability of repeat doses of TH104
研究概览
简要总结
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.
详细描述
Following written informed consent, participants with PBC and pruritus will be screened to establish study eligibility. Eligible participants will participate in a one-week observation period for baseline recording, to train participants in the use of electronic PRO tools, and establish baseline itch scores. Another eligibility assessment will be done at the end of this observation period (i.e., at baseline [Day 0]) to ensure that no changes in eligibility have occurred and to confirm that the participant remains eligible. At the baseline visit, participants will be randomized to receive placebo or TH104 treatment. Block randomization will be used, in a 1:2 ratio of placebo:TH104. Treatment will start with a 1-week dose escalation period in which participants will be escalated from 2 mg/day to 4 mg/day TH104 or matching placebo. This will be followed by 2 weeks of treatment with 8 mg and then 3 weeks of 16 mg of TH104 or matching placebo. Following the end of treatment, participants will enter a two-week follow-up period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged 18 to 75 years, inclusive, at the time of signing the informed consent form.
- •Diagnosis of PBC, as demonstrated by the participant presenting with at least 2 of the following criteria at the Screening Visit:
- •history of sustained increased alkaline phosphatase (ALP) levels first recognized at least 6 months prior to the Screening Visit
- •positive antimitochondrial antibodies (AMA) titer (>1:40 titer on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay [ELISA])
- •PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)
- •liver biopsy consistent with PBC Note: Participants with compensated cirrhosis will be eligible for enrollment only after the DSMB reviewed the safety and tolerability of TH104 in the first 10 non-cirrhotic participants.
- •Screening ALP value below 10 × upper limit of normal (ULN).
- •Participants taking the following drugs may be enrolled to the study, as long as they are on stable doses for > 12 weeks prior to the Screening Visit; Ursodeoxycholic acid (UDCA) Obeticholic acid Elafibranor Seladelpar Fibrates such as bezafibrate and fenofibrate Cholestyramine Antihistamines
- •Symptoms of pruritus - rated as NRS > 4 for worst daily score:
- •At screening AND
- •At least on 4 days during the 1-week baseline observation period.
- •A woman is eligible to participate if she is not breast-feeding or pregnant, as confirmed by a negative serum human chorionic gonadotrophin (hCG) test or at least one of the following conditions applies:
- •Non-reproductive potential defined as pre-menopausal with a documented tubal ligation or hysterectomy; or post-menopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40 mIU/mL and estradiol <40 pg/mL (<147 pmol/L) is confirmatory]. Women on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods along with either a second form of highly effective contraception or barrier protection (condoms with spermicide) if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment;
- •Reproductive potential and agrees to follow one of the contraception options methods for the specified duration of time.
- •For men participating in the study and having a female partner - birth control methods described above will have to be used throughout the study.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •Screening total bilirubin >2.0 x ULN.
- •Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >4 x ULN.
- •Screening serum creatinine >2.5 mg/dL (221 µmol/L).
- •History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).
- •History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease, definite autoimmune hepatitis or biopsy-proven non-alcoholic steatohepatitis (NASH/MASH/MAFLD).
- •Thyroid stimulating hormone (TSH) out of normal ranges.
- •Administration of the following drugs at any time during the 3 months prior to the Screening Visit: colchicine, methotrexate, azathioprine, opioids, opioids antagonists, or systemic corticosteroids.
- •Current or chronic history of inflammatory bowel disease, chronic diarrhea, Crohn's disease, or diarrhea related to malabsorption syndromes.
- •Based on averaged corrected QT interval (QTc) values of triplicate electrocardiograms (ECGs) obtained at least 5 minutes apart: QTc ≥450 msec; or QTc ≥480 msec in participants with Bundle Branch Block.
- •History of sensitivity to any of the study medications (or components thereof) or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation.
- •History of regular alcohol consumption within 6 months of the Screening Visit defined as an average weekly intake of >21 units for men or >14 units for women. One unit is equivalent to 8 g of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.
- •A positive screening drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids, and benzodiazepines.
- •Where participation in the study would result in blood in blood sampling in excess of 500 mL within a 56-day period.
- •Treatment with sertraline and/or rifampicin < 4 weeks prior to the Screening Visit.
- •Clinically significant abnormality of the buccal mucosa which could impact drug absorption.
- •Participation in a clinical trial with an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer) before the first dosing in this study.
- •Decompensated liver disease (encephalopathy, ascites, or Child Pugh score > 10 points). Participants with compensated cirrhosis will be eligible for enrollment after the DSMB reviewed the safety and tolerability of TH104 for the first 10 non-cirrhotic participants).
研究组 & 干预措施
Treatment
Experimental
干预措施: Nalmefene (Drug)
Control
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
The primary objective is to investigate the safety and tolerability of repeat doses of TH104
时间窗: 42 days
Percentage of participants with treatment-related adverse events as coded by MedDRA.
次要结局
- Difference in daily itch score between TH104 and placebo(42 days)
- Change in participants reported outcome for PBC-40 questionnaire(42 days)
- Change in participants reported outcome for 5-D itch questionnaire.(42 days)
- Change in participants reported outcome for EQ5D quality of life questionnaire(42 days)
- Change in Fatigue Severity Scale from baseline to the end of treatment.(42 days)
研究者
相似试验
尚未招募
2 期
Phase 2 Study of CU104 in Moderate-Severe Ulcerative ColitisUlcerative ColitisNCT05907330Curacle Co., Ltd.45
已完成
2 期
TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal AtrophyVulvovaginal AtrophyPainful IntercourseMenopauseDyspareuniaNCT02449902TherapeuticsMD50
终止
3 期
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative ColitisUlcerative ColitisNCT01805791Hutchison Medipharma Limited201
进行中（未招募）
2 期
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of ColchicineFamilial Mediterranean FeverFMFNCT05092776R-Pharm International, LLC84
已完成
1 期
Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy SubjectsHealthyNCT02667639R-Pharm35